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1 Research questions 
The HTA Core Model
®
 for Rapid Relative Effectiveness Assessment of 
Pharmaceuticals was used for structuring this report [1]. The Model organ-
ises HTA information according to pre-defined generic research questions. 
Based on these generic questions, the following research questions were an-
swered in the assessment. 
 
Element ID Research question 
Description of the technology 
B0001 What is ribociclib? 
A0022 Who manufactures ribociclib? 
A0007 What is the target population in this assessment? 
A0020 For which indications has ribociclib received marketing authorisation? 
Health problem and current use 
A0002 What is breast cancer? 
A0004 What is the natural course of breast cancer? 
A0006 What are the consequences of breast cancer for the society? 
A0023 How many people belong to the target population? 
A0005 What are the symptoms and the burden of breast cancer? 
A0003 What are the known risk factors for breast cancer? 
A0024 
How is breast cancer currently diagnosed according to published guidelines and in 
practice? 
A0025 
How is breast cancer currently managed according to published guidelines and in 
practice? 
Clinical effectiveness 
D0001 What is the expected beneficial effect of ribociclib on mortality? 
C0005 How does ribociclib affect symptoms and findings (severity, frequency) of breast cancer? 
D0006 How does ribociclib affect progression (or recurrence) of breast cancer? 
D0011 What is the effect of ribociclib on patients ̕ body functions? 
D0012 What is the effect of ribociclib on generic health-related quality of life? 
D0013 What is the effect of ribociclib on disease-specific quality of life? 
Safety 
C0008 How safe is ribociclib in relation to the comparator(s)? 
C0002 Are the harms related to dosage or frequency of applying ribociclib? 
C0005 
What are the susceptible patient groups that are more likely to be harmed through the 
use of ribociclib? 
A0021 What is the reimbursement status of ribociclib? 
 
 
 
 
EUnetHTA 
HTA Core Model® 
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2 Drug description 
Generic/Brand name/ATC code:  
Ribociclib/LEE011 
 
B0001: What is ribociclib? 
Ribociclib (LEE011) is a selective cyclin-dependent kinase inhibitor. It 
helps slow the progression of cancer by inhibiting two proteins, the cyclin-
dependent kinase 4 and 6 (CDK 4/6), which interact with cyclin D1. There-
by, the retinoblastoma (Rb) protein phosphorylation is inhibited and CDK-
mediated G1 to S phase transitions are prevented [2, 3]. As a consequence, 
the cell cycle in the G1 phase is arrested, which stops the cancer cell growth 
[4-10]. 
 
According to clinical trials, the recommended dose of ribociclib is 600 mg 
administered orally every day for three weeks followed by one week off in 
combination with 2.5 mg of letrozole daily, given continuously [6, 11, 12]. 
 
A0022: Who manufactures ribociclib? 
Novartis Pharmaceuticals 
 
 
 
3 Indication 
A0007: What is the target population in this assessment? 
Ribociclib is indicated for the first-line therapy in postmenopausal women 
with locally confirmed hormone-receptor (HR)-positive, human epidermal 
growth factor receptor 2 (HER2)-negative recurrent or metastatic breast 
cancer (MBC), who have not undergone systemic treatment for advanced 
disease [11, 13, 14]. 
 
 
 
4 Current regulatory status 
A0020: For which indications has ribociclib received marketing authorisa-
tion? 
Ribociclib has not yet been approved by the US Food and Drug Administra-
tion (FDA). However, it received priority review in conjunction with the 
older aromatase inhibitor (AI) letrozole as a first-line treatment in postmen-
orally bioavailable, 
selective, small-molecule 
inhibitor of CDK 4/6  
600 mg/day for 3 weeks, 
1 week off  
HR-positive, HER2-
negative recurrent or 
MBC  
priority review for 
ribociclib in  
November 2016  
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opausal women with HR-positive, HER2-negative recurrent or MBC in No-
vember 2016 [15]. 
Currently, ribociclib does not have a marketing authorisation in Europe for 
any indication, but the European Medicines Agency (EMA) has accepted 
the drug for review in the same patient population as the FDA [15, 16]. 
 
 
 
5 Burden of disease 
A0002: What is breast cancer? 
Owing to the molecular pathogenesis of breast cancer, it is designated as a het-
erogeneous malignancy. It arises from the tissues of the breast and most 
commonly originates in the cells that line the ducts due to dysregulation of 
the cell cycle. Breast cancer can be characterised by the pattern of expression 
of the HRs (oestrogen receptor [ER] and progesterone receptor [PR]), the 
HER2 receptor, a clinically relevant third molecular marker, the stage of di-
agnosis and the rate of growth [17]. Prognostically and therapeutically a dis-
tinction can be made between precancerous conditions like in situ tumours 
(obligatory precancerous condition: ductal carcinoma in situ [DCIS]; optional 
precancerous condition: lobular carcinoma in situ [LCIS]) and invasive breast 
cancer. 
 
A0004: What is the natural course of breast cancer? 
Mostly, cancer begins in the cells of the ducts. Abnormal cells are found in 
the lining of the ducts; however, they have not spread into the surrounding 
tissue and thus state a precancerous condition like DCIS (stage 0) [18, 19]. 
Normally, LCIS accompanies DCIS, whereas aggressive subtypes often do 
not show DCIS. In fact, the development of type A, ductal hyperplasia over 
DCIS, into invasive breast cancer is not veritable. Invasive breast cancer 
(stage I) is restricted to the area where the first abnormal cells arose. In stage 
II, abnormal cells have spread beyond the ducts or glands into the breast tis-
sue (invasive ductal carcinoma [IDC] or invasive lobular carcinoma [ILC]). 
Stage III breast cancer is stratified according to the tumour size and in-
cludes tumours >5 cm involving the skin, underlying muscle or the lymph 
nodes [20]. If the cancer has spread to distant parts of the body (stage IV) via 
the lymph system or the blood, it can also be referred to as MBC [21].  
Breast cancer can be staged by using the American Joint Committee on Can-
cer (AJCC) tumour node metastasis (TNM) staging system. It involves im-
portant tumour characteristics as well as survival data to support the estima-
tion of outcomes. The TNM staging system classifies tumours on the basis of 
primary tumour characteristics (T), the presence or absence of regional 
lymph node involvement (N), and the presence or absence of distant metas-
tases (M). The TNM staging system is especially relevant for inflammatory 
and stage IV breast cancer.  
 
 
ribociclib has not yet 
been approved by the 
EMA 
heterogeneous disease 
that arise from the 
tissue of the breast 
stages of breast cancer 
AJCC-TNM staging 
system 
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A0006: What are the consequences of breast cancer for the society? 
Due to the aging population and in combination with the fact that higher 
age is a main risk factor for cancer, the incidence of cancer will increase over 
time [22, 23]. Globally, around 30.0% of the patients with early breast cancer 
develop advanced or MBC [20]. In Austria, breast cancer accounts for ap-
proximately 28,000 (2.6% of total) life-years lost due to premature deaths 
[24]. Moreover, the incidence of breast cancer is highest for higher socioeco-
nomic groups, whereas survival is lowest in lower socioeconomic groups 
[16]. 
 
A0023: How many people belong to the target population? 
About 30.0% of all malignant neoplasm cases in Austria are due to breast 
cancer. It is the most common cause of death due to cancer in females. The 
age standardised incidence rate for the European Standard Population 
(2013) is 64.3 per 100,000 persons per year. In 2014, 5,454 persons were new-
ly diagnosed with breast cancer in Austria, of whom approximately 98.0% 
were women. Moreover, around 86.0% of female breast cancer patients and 
78.0% of male breast cancer patients (all stages are included) are alive at 
least five years after diagnosis [25]. The median age at diagnosis of breast 
cancer is 62 years, ranging from 55 to 64 years [21]. HR-positive disease ac-
counts for approximately 65.0% and 80.0% of breast cancers in pre- and 
postmenopausal women, respectively. Accounting for approximately 70.0% 
of breast cancer patients, HR-positive and HER2-negative is the most com-
mon type of breast cancer. Between 5.0%–10.0% of the patients are primari-
ly diagnosed with MBC that has spread to other parts of the body, e.g., bone, 
liver, lung and brain [20]. 
 
A0005: What are the symptoms and the burden of breast cancer? 
A hard, immovable, single dominant lesion (breast mass) with irregular bor-
ders is the most common symptom of breast cancer [21, 26, 27]. In addition, 
symptoms like swelling of the whole or only parts of the breast, skin irrita-
tion or dimpling (peau d’orange), breast or nipple pain, nipple retraction, 
redness, scaliness, thickening of the nipple or breast skin, nipple discharge 
or axillary adenopathy can occur [21, 27, 28]. In advanced stages of breast 
cancer weight loss and reduced performance can be present [28]. Symptoms 
due to metastases include swelling of the arm by lymphedema in lymph 
node metastases of the axilla, bone pain in skeletal metastases, cough and 
dyspnoea in pulmonary and/or pleural metastases, jaundice and hepatic 
failure in advanced liver metastases, or neurological symptoms in cerebral 
metastases [16, 21, 28]. 
 
A0003: What are the known risk factors for breast cancer? 
Established high-risk factors for developing breast cancer are an increasing 
age, female gender and white race. Indeed, obesity as well as certain genes 
like BRCA1, BRCA2 and TP53 are associated with an increased risk of 
breast cancer in premenopausal and postmenopausal women [16, 28-31]. In 
addition, increased exposure to oestrogen like early menarche or late meno-
pause can also be a risk factor for the diagnosis of breast cancer [28, 29]. 
Furthermore, reproductive factors that increase risk are a first pregnancy at 
increasing incidence of 
cancer  
 
 
 
highest incidence rate in 
higher socioeconomic 
groups  
incidence rate based on 
the European Standard 
Population: 64.3 per 
100,000 persons/year 
 
 
 
median age at diagnosis: 
62 
 
 
HR-positive, HER2-
negative most common 
type of breast cancer  
main symptoms:  
breast mass,  
skin irritation,  
pain  
main risk factors:  
age, gender, race,  
obesity, genes, 
menopausal status  
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late age, absence of breastfeeding and nulliparity [29, 30]. Other risk factors 
that may lead to breast cancer are alcohol consumption, smoking, family and 
personal history of breast cancer [30]. 
 
A0024: How is breast cancer currently diagnosed according to published 
guidelines and in practice? 
There are several ways to diagnose breast cancer, such as the clinical breast 
exam (CBE), the x-ray mammography or radiological examinations like the 
ultrasound exam or magnetic resonance imaging (MRI). However, an ab-
normal mammogram detected in countries with established screening pro-
grams is the most common reason for suspecting breast cancer. If breast 
cancer is suspected via a mammography, a biopsy (punch biopsy and vacu-
um-assisted biopsy) is performed. An additional breast MRI can increase 
the detection rate of additional lesions, but it does not improve the progno-
sis. In the later stage of the disease, liver function tests, brain MRIs, ab-
dominal diagnostic scans, bone scans, sodium fluoride positron emission 
tomographies (PETs) or fluorodeoxyglucose (FDG) can be applied [28, 31]. 
As breast cancer is a heterogeneous disease, it is essential to establish HR 
and HER2 status [18, 31]. Additionally, the stratification into the different 
disease stages, described in the section “A0004: What is the natural course of 
breast cancer?”, is crucial to ensure the best therapy.  
 
 
 
6 Current treatment 
A0025: How is breast cancer currently managed according to published 
guidelines and in practice? 
Generally, breast cancer can be treated by surgery, adjuvant irradiation or 
systemic therapies [28]. To determine which treatment strategy is the most 
suitable for the patient, several factors are important [28]: 
 stage of cancer (AJCC TNM staging system) 
 grade of disease 
 tumour site 
 menopausal status 
 patient health 
 HR and HER2 status 
 proliferation rate estimated by means of a Ki67 test 
The treatment of stage ≤3 breast cancer, where no distant metastases have 
been detected, has a curative intention and is dependent on the eligibility of 
a breast-conserving therapy (BCT) and whether it is a clinically node-
negative breast cancer. For patients who are eligible for a BCT, the following 
treatment options in this sequence may be applied [28]: 
 
 primary neoadjuvant systematic therapy (node-negative breast can-
cer) 
diagnosis of breast 
cancer via 
CBE, 
x-ray mammography, 
ultrasound exam, 
MRI, 
biopsy 
HR and HER2 status 
 
stratification into 
disease stages 
factors for treatment 
decisions 
curative treatment 
options for stage ≤ 3 
breast cancer  
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 surgery (sentinel lymph node biopsy [SLNB]) 
 axillary node dissection 
 adjuvant systematic therapy  
 adjuvant radiation therapy 
For patients who are not eligible for a BCT and for locally advanced breast 
cancer (stage IIB, IIIA/B), the previously mentioned treatment options can 
be applied as well. However, instead of a BCT, a mastectomy may be ap-
plied. In the case of metastatic disease (stage IV), treatment with a palliative 
intent (systematic therapy, best supportive care, etc.) can be used [28]. 
In particular, palliative treatment options for HR-positive, HER2-negative 
recurrent or MBC in postmenopausal women are:  
 
 local therapy, such as surgery or irradiation in case of an acute 
threat to organ functions, e.g., liver, lung, brain or sternum 
 first-line endocrine therapy for HR-positive postmenopausal pa-
tients: 
o endocrine therapy alone, followed by endocrine therapy 
plus CDK 4/6 inhibitors [28, 31-33] 
o endocrine therapy plus CDK 4/6 inhibitors, followed by 
endocrine therapy alone or combined with everolimus 
[28] 
o in case of rapid disease progression within the first few 
months  switching to chemotherapy in the second-line 
[34] 
 first-line chemotherapy for patients with rapidly progressive, symp-
tomatic disease or visceral metastases with end-organ dysfunction; 
after four to six months switching to maintenance endocrine thera-
py [34] 
 
 
 
7 Evidence 
A literature search was conducted on 27 December 2016 in five databases: 
the Cochrane Library, CRD Database, Embase, Ovid Medline and PubMed. 
Search terms were “ribociclib”, “LEE011”, “breast cancer”, “breast neo-
plasms” and “mamma carcinoma”. The manufacturer was also contacted 
and submitted 14 references (all of which had already been identified by sys-
tematic literature search). A manual search identified 26 additional refer-
ences (web documents and journal articles). Overall, 139 references were 
identified. Included in this report are:  
 One phase III study assessing ribociclib in HR-positive, HER2-
negative recurrent or MBC patients who have not undergone sys-
temic treatment for advanced disease [35] 
 One phase Ib/II study assessing the safety, tolerability, pharmaco-
kinetic profile and preliminary clinical antitumor activity of ribo-
ciclib and letrozole used in combination for HR-positive, HER2-
negative advanced breast cancer [36] 
stage IV breast cancer 
treatment options with 
a palliative intent 
endocrine stage IV 
treatment options  
chemotherapy 
systematic literature 
search in 5 databases: 
113 hits  
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The methodological quality of the evidence was conducted to assess the risk 
of bias at the study level based on the EUnetHTA internal validity for RCTs 
[37]. Evidence was assessed based on the adequate generation of the ran-
domisation sequence, allocation concealment, blinding of patient and treat-
ing physician, selective outcome reporting and other aspects that may in-
crease the risk of bias. Study quality details are reported in Table 4 of the 
Appendix. 
To evaluate the magnitude of clinically meaningful benefit that can be ex-
pected from a new anti-cancer treatment, the Magnitude of Clinical Benefit 
Scale developed by the European Society for Medical Oncology (ESMO-
MCBS) was used [38]. Additionally, an adapted version (due to perceived 
limitations) of the ESMO-MCBS was applied [39]. Further details about the 
ESMO-MCBS are reported in the discussion. 
 
7.1 Clinical efficacy and safety – 
phase III study
 
MONALEESA-2 [35] a randomised, double-blind, placebo-controlled phase 
III study was conducted to assess the efficacy and safety of the selective 
CDK 4/6 inhibitor ribociclib combined with letrozole for the first-line 
treatment in postmenopausal women with HR-positive, HER2-negative re-
current or MBC, who had not received previous systemic therapy for ad-
vanced disease.  
A total of 668 patients were enrolled to receive either a 600 mg daily dose of 
ribociclib for three weeks and one week off, plus a daily dose of 2.5 mg of 
letrozole (n = 334) or placebo with letrozole (n = 334). The randomisation 
was stratified according to the presence or absence of liver or lung metasta-
ses. In order to detect a hazard ration of 0.67 with a power of 93.5% at a one-
sided alpha level of 0.025, 302 patients who had disease progression or died 
were required. 
After at least 211 (70.0% of 302) patients had disease progression or died, 
the interim analysis was released. Finally, due to a delay in reporting from 
local trial centres, the results of 243 patients who had disease progression or 
died were reported and 302 patients were on treatment at the time of data 
cut-off (January 2016). Moreover, the median duration of follow-up was 15.3 
months at the time of data cut-off. 87 (26.0% of 334) patients of the inten-
tion-to-treat population discontinued treatment due to disease progression 
in the ribociclib group, compared to 146 (44.0% of 334) patients of the inten-
tion-to-treat population in the placebo group.  
Enrolled patients were postmenopausal women with a median age of 62 
years. All patients had HR-positive disease and all but one patient in each 
group had HER2-negative disease. A total of 227 (34.0% of 668) patients had 
newly diagnosed advanced or metastatic disease. Detailed patient character-
istics can be found in Table 3 of the Appendix, together with inclusion and 
exclusion criteria. 
The primary endpoint of the MONALEESA-2 trial was locally assessed PFS, 
according to RECIST (response evaluation criteria in solid tumours) version 
1.1. Secondary outcomes comprised the proportion of patients with overall 
response (ORR) and clinical benefit (CBR), overall survival (OS), safety and 
study level risk of bias 
assessed based on 
EUnetHTA internal 
validity for RCTs 
magnitude of clinically 
meaningful benefit 
assessed based on 
ESMO-MCBS  
MONALEESA-2: 
randomised,  
double-blind,  
placebo-controlled 
phase III study 
(n = 668)  
daily dose of 600 mg  
 
 
 
hazard ratio of 0.67 
time of data cut-off: 
results of 243 patients 
reported 
 
median follow-up 
duration: 15.3 months  
median age of 62 years  
primary endpoint: 
locally assessed PFS, 
main secondary 
endpoints:  
ORR, CBR, OS, safety 
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quality-of-life (QoL). Exploratory endpoints included pharmacokinetic and 
biomarkers of response or resistance. However, the results of the QoL as-
sessments and the exploratory analyses were not reported in the study. 
 
7.1.1 Clinical efficacy 
D0001: What is the expected beneficial effect of ribociclib on mortality? 
At the time of data cut-off the median OS has not been reached. In the ribo-
ciclib group 23 deaths had occurred, while 20 deaths occurred in the placebo 
group. Table 1 represents the efficacy of ribociclib. 
 
D0006: How does ribociclib affect progression (or recurrence) of breast 
cancer? 
At the time of data cut-off (January 2016), the median duration of PFS in 
the placebo group was 14.7 months (13.0–16.5), but was not reached in the 
ribociclib group. However, the rate of locally assessed PFS was significantly 
higher in the treatment group compared to the control group. The estimated 
12-month PFS rate was 72.8% (67.3–77.6) in the ribociclib group and 60.9% 
(55.1–66.2) in the placebo group. After 18 months, the PFS rate was 63.0% 
(54.6–70.3) and 42.2% (34.8–49.5) respectively. 
 
D0005: How does ribociclib affect symptoms and findings (severity, fre-
quency) of breast cancer? 
The ORR was 40.7% (35.4–46.0) in the ribociclib group and 27.5% (22.8–
32.8) in the placebo group of the intention-to-treat population and 52.7% 
(46.6–58.9) and 37.1% (31.1–43.2) respectively among patients with measur-
able disease. The CBR was 79.6% (75.3–84.0) in the ribociclib group and 
72.8% (68.0–77.5) in the placebo group of the intention-to-treat population 
and 80.1% (75.2–85.0) and 71.8% (66.2–77.5), respectively, among patients 
with measurable disease.  
 
D0011: What is the effect of ribociclib on patients̕ body functions? 
No evidence was found to answer this research question. 
 
D0012: What is the effect of ribociclib on generic health-related quality of 
life? 
D0013: What is the effect of ribociclib on disease-specific quality of life? 
The results of the QoL assessments were not reported in the MONALEESA-
2 trial. 
 
 
 
 
 
median OS has not  
been reached with 23 
versus 20 deaths in the 
ribociclib group  
ribociclib significantly 
improved the locally 
assessed PFS rate  
improved ORR and  
CBR in the ribociclib 
group compared to  
the placebo group  
QoL assessments 
were not reported  
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Table 1: Efficacy results of MONALEESA-2 trial  
Descriptive statistics and 
estimate variability (data 
cut-off 24 January 2016) 
Treatment group Ribociclib Placebo 
Number of subject 334 334 
Median PFS, months NR (19.3–NR) 14.7 (13.0–16.5) 
12-month PFS rate, % 72.8 (67.3–77.6) 60.9 (55.1–66.2) 
18-month PFS rate, % 63.0 (54.6–70.3) 42.2 (34.8–49.5) 
OS NR NR 
QoL NR NR 
ORR  
intention-to-treat, % 
 
ORR 
measurable disease, % 
 
40.7 (35.4–46.0) 
 
 
52.7 (46.6–58.9) 
 
27.5 (22.8–32.8) 
 
 
37.1 (31.1–43.2) 
CBR 
intention-to-treat, % 
 
CBR 
measurable disease, % 
 
79.6 (75.3–84.0) 
 
 
80.1 (75.2–85.0) 
 
72.8 (68.0–77.5) 
 
 
71.8 (66.2–77.5) 
Effect estimate  
per comparison Comparison groups 
ribociclib+letrozole 
versus 
placebo+letrozole 
median PFS 
HR 0.56 
95% CI 0.43–0.72 
Two-sided log-rank test 
p value 
p = 3.29x10-6 
ORR Two-sided log-rank test 
p value 
p <0.001 
CBR 
Two-sided log-rank test 
p value 
p = 0.020 
Abbreviations: CI = confidence interval, HR = hazard ratio, PFS = progression-free survival, OS = overall sur-
vival, QoL = quality of life, ORR = overall response rate, CBR = clinical benefit rate, NR = not reported 
 
7.1.2 Safety 
C0008: How safe is ribociclib in relation to the comparator(s)? 
In the safety population including 334 patients in the ribociclib group and 
330 patients in the placebo group, only patients who received at least one 
dose of study regimen and who had at least one safety assessment after base-
line were included. Adverse events (AEs) occurred in at least 35% of the pa-
tients in either group. The AEs included neutropenia (74.3% in the ribo-
ciclib group and 5.2% in the placebo group), nausea (51.5% and 28.5%), in-
fections (50.3% and 42.4%), fatigue (36.5% and 30.0%), and diarrhoea 
(35.0% and 22.1%). Most of these AEs were of grade 1 or 2. AEs of grade ≥3 
occurred in 81.2% of the ribociclib patients and in 32.7% of the patients re-
ceiving placebo. In fact, this is an increase of 48.5% in grade 3 or 4 AEs in 
the ribociclib group. The most common grade 3 or 4 AEs in the ribociclib 
group (≥5% of the patients in either group) were neutropenia (59.3% and 
0.9%), leukopenia (21.0% and 0.6%), hypertension (9.9% and 10.9%), in-
creased alanine aminotransferase level (9.3% and 1.2%), lymphopenia (6.9% 
and 0.9%) and increased aspartate aminotransferase level (5.7% and 1.2%). 
most common grade 3-4 
AEs:  
neutropenia, 
leukopenia, 
hypertension,  
increased alanine 
aminotransferase level, 
lymphopenia,  
increased aspartate 
aminotransferase level 
4 AE-related deaths  
Horizon Scanning in Oncology 
14 LBI-HTA | 2017 
Moreover, serious AEs occurred in 71 patients (21.3%) in the ribociclib 
group and in 39 (11.8%) in the placebo group during the treatment. Addi-
tionally, four AE-related deaths in the ribociclib group and one in the place-
bo group were stated. All treatment-emergent AEs can be found in Table 2.  
 
C0002: Are the harms related to dosage or frequency of applying ribociclib? 
In a total of 54.0% of the ribociclib group and 7.0% of the placebo group, 
dose reductions were required most commonly due to AEs. Interruptions in 
the dose of ribociclib occurred in 257 patients (77.0%) and of letrozole in 
132 patients (40.0%) in the ribociclib group. Among the 330 patients in the 
placebo group, placebo was interrupted in 134 (41.0%) and letrozole in 107 
patients (32.0%).  
 
C0005: What are the susceptible patient groups that are more likely to be 
harmed through the use of ribociclib? 
Patients with a historic cardiac disease or dysfunction including a QT inter-
val corrected for heart rate according to Fridericia’s formula (QTcF) of 
>450 msec at screening are more likely to be harmed through the use of ri-
bociclib [35]. Therefore, patients with cardiac disease or a dysfunction were 
excluded from the study. 
 
Table 2: Most frequent adverse events
1
 
 
Adverse Event (according  
to CTCAE version 4.03) 
 
Ribociclib (n = 334) Placebo (n = 330) 
 Any Grade 
n (%) 
Grade 3-4 
n (%) 
Any Grade 
n (%) 
Grade 3-4 
n (%) 
Any disease-related AEs 329 (98.5) 271 (81.2) 320 (97.0) 108 (32.7) 
Neutropenia 248 (74.3) 198 (59.3) 17 (5.2) 3 (0.9) 
Nausea 172 (51.5) 8 (2.4) 94 (28.5) 2 (0.6) 
Infections 168 (50.3) 14 (4.2) 140 (42.4) 8 (2.4) 
Fatigue 122 (36.5) 8 (2.4) 99 (30.0) 3 (0.9) 
Diarrhoea 117 (35.0) 4 (1.2) 73 (22.1) 3 (0.9) 
Alopecia 111 (33.2) NA 51 (15.5) NA 
Leukopenia 110 (32.9) 70 (21.0) 13 (3.9) 2 (0.6) 
Vomiting 98 (29.3) 12 (3.6) 51 (15.5) 3 (0.9) 
Arthralgia 91 (27.2) 3 (0.9) 95 (28.8) 3 (0.9) 
Constipation 83 (24.9) 4 (1.2) 63 (19.1) 0 (0) 
Headache 74 (22.2) 1 (0.3) 63 (19.1) 1 (0.3) 
Hot flash 70 (21.0) 1 (0.3) 78 (23.6) 0 (0) 
Back pain 66 (19.8) 7 (2.1) 58 (17.6) 1 (0.3) 
 
                                                             
1
 AEs occurring in at least 15% of patients in any group. 
54.0% ribociclib dose 
reductions,  
77.0% of the patients 
dose interruption of 
ribociclib  
 
cardiac disease or 
dysfunction  
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Cough 65 (19.5) 0 (0)2 59 (17.9) 0 (0)2 
Anaemia 62 (18.6) 4 (1.2) 15 (4.5) 4 (1.2) 
Decreased appetite 62 (18.6) 5 (1.5) 50 (15.2) 1 (0.3) 
Rash 57 (17.1) 2 (0.6) 26 (7.9) 0 (0) 
Increased alanine amino-
transferase 
52 (15.6) 31 (9.3) 13 (3.9) 4 (1.2) 
Increased aspartate amino-
transferase 
50 (15.0) 19 (5.7) 12 (3.6) 4 (1.2) 
Abbreviation: CTCAE = Common Terminology Criteria for Adverse Events, NA = not applicable 
 
7.2 Clinical effectiveness and safety – further studies 
A multicentre, open-label phase Ib/II study was conducted to assess the safe-
ty, tolerability, pharmacokinetic profile, as well as the preliminary clinical 
antitumor activity of ribociclib, alpelisib and letrozole used in combination 
for HR-positive, HER2-negative advanced breast cancer. In the phase II 
study three arms were compared, the first of which is of particular interest 
for this assessment: As of 22 August 2014, 29 patients had been treated with 
ribociclib (daily 600 mg for three weeks and one week off) in combination 
with letrozole (2.5 mg/day continuously). 
Treatment discontinuations were mostly due to disease progression and oc-
curred in 35% of the patients. The most common all-grade drug-related AEs 
were neutropenia (72.0%) and nausea (35.0%). Moreover, the most common 
grade 3-4 drug-related AE, neutropenia, occurred in 52.0% of the patients. 
Furthermore, there has been one confirmed partial response, seven patients 
with stable disease and six patients with neither complete response nor pro-
gressive disease. The patient with the confirmed partial response had been 
pre-treated with the AI fulvestrant and a PI3K/AKT/mTOR inhibitor and 
had PIK3CA and TP53 mutations [36]. 
 
 
 
8 Estimated costs 
A0021: What is the reimbursement status of ribociclib? 
To date, ribociclib has not been approved in the US or in Europe. No price 
estimates are therefore available at this point.  
 
 
 
                                                             
2
 Data for the respective grade 4 AE were not applicable, since they are not included 
in the CTCAE. 
P5-19-24:  
efficacy, safety and 
pharmacokinetic profile 
of ribociclib in HR-
positive and HER2-
negative advanced 
breast cancer  
 
ribociclib combined with 
letrozole demonstrated 
grade 3-4 neutropenia in 
52.0% of the patients  
no cost estimates 
available yet 
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9 Ongoing research 
In January 2016, a search in the databases www.clinicaltrials.gov and 
www.clinicaltrialsregister.com was conducted. The following three ongoing 
phase III trials are investigating ribociclib in pre- or postmenopausal women 
with HR-positive, HER2-negative advanced breast cancer: 
 NCT02941926 (COMPLEEMENT-1): An open-label, multicentre, 
phase IIIb study is assessing the safety and efficacy of ribociclib in 
combination with letrozole for the treatment of men and postmeno-
pausal women with HR-positive, HER2-negative advanced breast 
cancer, who had not received prior hormonal therapy for advanced 
disease. Estimated study completion date is November 2020. 
 NCT02422615 (MONALEESA-3): A randomised, double-blind, 
placebo-controlled, international phase III study is evaluating the 
efficacy and safety of ribociclib or matching placebo in combination 
with fulvestrant in men and postmenopausal women with HR-
positive, HER2-negative advanced breast cancer, who have received 
no or only one line of prior ET for advanced disease. As of 20 April 
2016, the phase III study is open at approximately 220 sites in 29 
countries and global recruitment is ongoing with a target accrual of 
approximately 660 patients worldwide [40]. Estimated study com-
pletion date is February 2020. 
 NCT02278120 (MONALEESA-7): A randomised, double-blind, 
placebo-controlled phase III study, in which pre- or perimenopau-
sal women with HR-positive, HER2-negative advanced breast can-
cer are treated with goserelin and either tamoxifen or NSAI plus ri-
bociclib or matching placebo. As of 2 February 2016, the phase III 
study is open at 237 sites in 30 countries and global recruitment is 
ongoing with a planned target accrual of approximately 660 pa-
tients [41]. Estimated study completion date is February 2018. 
Currently, two studies are ongoing in different treatment lines and regimens 
in patients with HR-positive, HER2-negative advanced breast cancer (e.g., 
NCT01857193, NCT02732119). In addition, ribociclib is also being investi-
gated for other indications like glioblastoma, solid tumours, endometrial 
carcinoma, prostate carcinoma, liposarcoma, squamous cell carcinoma of the 
head and neck, teratoma. 
 
 
 
10 Discussion 
The CDK 4/6 inhibitor ribociclib has not yet been approved by the US FDA 
or by the EMA. However, in November 2016 the FDA approved priority re-
view for ribociclib in conjunction with the older AI letrozole as a first-line 
therapy of postmenopausal women with HR-positive, HER2-negative recur-
rent or MBC. The EMA has accepted the drug for review in the same patient 
population as the FDA [15, 16]. 
3 phase III studies are 
ongoing, investigating 
ribociclib in patients 
with HR-positive, HER2 
negative advanced 
breast cancer  
2 ongoing studies 
(phase I and II) in 
different treatment lines 
and regimes 
 
no marketing 
authorisation in the  
US and in the EU  
Ribociclib in combination with letrozole for HR-positive, HER2-negative recurrent or metastatic breast 
cancer 
LBI-HTA | 2017 17 
This report is based on the interim analysis of the randomised, double-blind, 
placebo-controlled MONALEESA-2 phase III study, which assessed the 
safety and efficacy of ribociclib in combination with letrozole for postmeno-
pausal women with HR-positive, HER2-negative recurrent or MBC. The re-
sults of the interim analysis were reported after disease progression or death 
had occurred in 243 patients. OS outcomes were not mature, with 23 deaths 
in the ribociclib group and 20 deaths in the placebo group at the time of da-
ta cut-off. Additionally, no data on PFS in months and QoL were available. 
However, ribociclib plus letrozole recipients showed an improvement in the 
primary endpoint of PFS (72.8% vs. 60.9%, 12-month PFS rate; 63.0% vs. 
42.2%, 18-month PFS rate), as well as in the ORR (40.7% vs. 27.5%, inten-
tion-to-treat population) and in the CBR (79.6% vs. 72.8%, intention-to-
treat population) compared to placebo recipients. 
Due to the fact that the median duration of OS and PFS had not been 
reached in the ribociclib group, the ESMO-MCBS, as well as its adapted ver-
sion, could not have been applied. Consequently, the magnitude of the clini-
cally meaningful benefit of ribociclib could not have been assessed accurate-
ly. Hence, further studies are needed to investigate the gain in the median 
duration of OS and PFS of ribociclib compared to the placebo. 
Grade 3 or 4 neutropenia, leukopenia, hypertension, increased alanine ami-
notransferase level, lymphopenia, and increased aspartate aminotransferase 
level occurred in ≥5% of the patients in either group. However, the ribo-
ciclib group showed an increase of AEs of grade ≥3 of 48.5% compared to 
the placebo group. Additionally, AEs of any grade including neutropenia, 
nausea, infections, fatigue and diarrhoea were significantly more common in 
the ribociclib group. Furthermore, 54.0% of the ribociclib recipients needed 
a dose reduction due to an AE and 77.0% required a dose interruption. 
In the MONALEESA-2 study, results of biomarker analyses and QoL as-
sessments had not been reported. However, considering the fact that CDK 
4/6 inhibitors are known to cause significant AEs, the identification of bi-
omarkers is crucial [42]. Therefore, further investigations are necessary to 
assess potential biomarkers in order to identify the patients with the greatest 
clinical benefit and, as a result, enrich the responsive patient population [43, 
44]. Moreover, as no QoL outcomes had been outlined in the study, uncer-
tainty exists whether the efficacy of ribociclib overrules its AEs. Thus, it is 
important to include QoL assessments in future studies to take into account 
the burden a specific health state places upon a person, as well as which val-
ue a person assigns to his or her health state [45]. 
Furthermore, patients were not stratified according to molecular subtypes, 
but rather based on the presence or absence of liver or lung metastases. 
However, especially among patients with luminal B tumours there might be 
variations in ER and PR expressions between the different disease stages. 
On these grounds, it might be necessary to stratify the patients according to 
molecular subtypes to enable a more accurate assessment of the benefit of 
ribociclib in the different subtypes of advanced breast cancer [46]. 
 
report based on interim 
analysis of the 
MONALLEESA-2  
phase III study 
 
 
 
no data on PFS in 
months and QoL 
available 
ESMO-MCBS on clinical 
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stratification according 
to molecular subtypes  
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Currently, the CDK 4/6 inhibitor ribociclib is also being investigated in pa-
tients with early breast cancer and for other indications like glioblastoma, 
solid tumours, endometrial carcinoma, prostate carcinoma, liposarcoma, 
squamous cell carcinoma of the head and neck and teratoma. In the US, the 
first CDK 4/6 inhibitor, palbociclib, received marketing authorisation in 
combination with letrozole as first-line treatment for postmenopausal wom-
en with HR-positive, HER2-negative advanced breast cancer in February 
2015. In February 2016 licensing was expanded to include palbociclib plus 
fulvestrant for women with HR-positive, HER2-negative advanced or MBC 
with disease progression during or following ET. In November 2016 palbo-
ciclib was approved by the EMA for the same indications. Additionally, a 
third CDK 4/6 inhibitor, abemaciclib, is under development for the treat-
ment of breast cancer [47, 48]. A comparison of the two CDK 4/6 inhibitors, 
palbociclib and ribociclib, might be necessary in order to investigate which 
the patients would benefit the most from. Furthermore, it might be crucial 
to assess the impact of the treatment with CDK 4/6 inhibitors on the endo-
crine sensitivity of subsequent therapies. 
Reimbursement decisions are based on crucial factors including clinical ef-
fectiveness, costs, safety, etc. However, there is no efficacy evidence in terms 
of an OS improvement of ribociclib in combination with letrozole compared 
to placebo. Moreover, there are no price estimates available for ribociclib, as 
it has not yet received marketing authorisation in the US or in Europe. In 
this case, the costs of palbociclib of €4,582.55 per 28-day cycle could be taken 
as a proxy variable for ribociclib costs, since both drugs have the same cycle 
length and are indicated for the same target population [49]. 
Overall, even if the addition of ribociclib to letrozole increases the rate of 
toxicity significantly, there may be a benefit gained from adding it, since ri-
bociclib increased the PFS rate by 11.9% and 20.8% (12 months vs. 18 
months). However, apart from this, no evidence regarding the comparative 
OS advantage of ribociclib in combination with letrozole and no median 
gain in PFS in months could have been reported. Nevertheless, it might be 
crucial to investigate the impact of the treatment with CDK 4/6 inhibitors 
on the endocrine sensitivity of subsequent therapies. Furthermore, the effec-
tiveness of ribociclib has not been supported by QoL outcomes. These and 
potential biomarkers should be reported in order to identify the target pa-
tient population benefitting the most from the treatment of ribociclib. Final-
ly, the stratification according to molecular subtypes may lead to a more ac-
curate assessment of the benefit of ribociclib.  
first CDK 4/6 inhibitor, 
palbociclib, received 
marketing authorisation 
in the US and EU 
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12 Appendix  
Table 3: Characteristics of the MONALEESA-2 trial 
Title: Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer 
Study identifier NCT01958021, EudraCT 2013-003084-61, MONALEESA-2 
Design 
Randomised, double-blind, placebo-controlled, phase III trial 
Duration of main phase 
(interim analysis): 
24 January 2014 to 24 March 2015 + ongoing follow-up 
Duration of run-in phase: NA 
Duration of extension phase: NA 
Hypothesis 
Superiority 
The study was designed to assess the efficacy and safety of the selective CDK 4/6 inhibitor ribo-
ciclib combined with letrozole for the first-line treatment in postmenopausal women with HR-
positive, HER2-negative recurrent or MBC, who had not received previous systemic therapy for 
advanced disease. A pre-planned interim analysis was planned on 29 January 2016, after 211 pa-
tients had disease progression or died. Pre-specified criteria for superiority required a hazard ratio 
of 0.56 or less with p<1.29 x 10-5. 
Funding Novartis Pharmaceuticals 
Treatments groups 
 
Ribociclib group (n = 334) 
600 mg ribociclib per day on a 3-weeks-on, 1-week-off 
schedule in combination with 2.5 mg of letrozole per day 
(continuously) 
Placebo group (n = 334) Placebo combined with letrozole 
Endpoints and definitions 
 
Progression-free 
survival PFS 
Number of days from the date of first dose to the date of 
earliest disease progression or death 
Overall response 
rate ORR 
Overall CR or PR according to RECIST v1.1. Proportion of 
participants with CR or PR relative to all randomised par-
ticipants and randomised participants with measurable 
disease at baseline, assessed up to 12 months 
Clinical benefit 
rate CBR 
Overall response plus stable disease lasting 24 weeks or 
more 
Overall survival OS Number of days from the date of first dose to the date of 
death for all dosed patients 
Database lock Last verified: August 2016 
Results and analysis  
Analysis description Primary analysis 
The primary endpoint was assessed once 243 patients had disease progression or died. Efficacy 
analyses (primary and secondary endpoints) were performed in the intention-to-treat population, 
which was defined as all randomly assigned patients. Safety analyses were performed in the safety 
population, which was defined as all patients who received at least one dose of study treatment 
and who had at least one safety assessment after base-line. A determination that 302 patients had 
disease progression or died was required to detect a hazard ratio of 0.67 with a power of 93.5% at a 
one-sided alpha level of 0.025 with the use of a two-look Haybittle-Peto efficacy stopping bounda-
ry. A stratified Cox regression analysis was performed to estimate the hazard ratio and 95% confi-
dence interval of progression-free survival. 
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Title: Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer 
Study identifier NCT01958021, EudraCT 2013-003084-61, MONALEESA-2 
Analysis population  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inclusion criteria 
 postmenopausal women 
 locally confirmed HR-positive, HER2-negative recurrent 
or MBC 
 without previous systematic therapy for advanced dis-
ease 
 measureable disease according to Response Evaluation 
Criteria in Solid Tumours [RECIST], version 1.1 
 OR at least one predominantly lytic bone lesion, along 
with an Eastern Cooperative Oncology Group perfor-
mance status of 0 or 1 
 adequate bone marrow and organ function 
 
Exclusion criteria 
 previous CDK 4/6 inhibitor or any previous systemic 
chemotherapy 
 OR previous ET for advanced disease 
 previous neoadjuvant or adjuvant therapy with a non-
steroidal AI, unless disease-free interval was more than 
12 months 
 patients with inflammatory breast cancer 
 patients with CNS metastases 
 patients with a history of cardiac disease or dysfunction 
(including a QT interval corrected for heart rate accord-
ing to Fridericia’s formula [QTcF] of >450 msec at 
screening) 
 patients with impaired gastrointestinal function that 
altered drug absorption 
 
Characteristics 
 
Ribociclib Placebo 
Median age (range), years 62 (23-91) 63 (29-88) 
Race 
     White, n (%) 
     Asian,  n (%) 
     Black,  n (%) 
     Other or unknown, 
     n (%) 
269 (80.5) 
28 (8.4) 
10 (3.0) 
27 (8.1) 
280 (83.8) 
23 (6.9) 
7 (2.1) 
24 (7.2) 
ECOG performance status, 
n (%) 
     0 
     1 
 
 
205 (61.4) 
129 (38.6) 
 
 
202 (60.5) 
132 (39.5) 
Disease stage, n (%) 
     III 
     IV 
1 (0.3) 
333 (99.7) 
3 (0.9) 
331 (99.1) 
Hormone-receptor status, 
n (%) 
     ER-positive 
     PR-positive 
 
 
332 (99.4) 
271 (81.1) 
 
 
333 (99.7) 
278 (83.2) 
Disease-free interval, n (%) 
   Newly diagnosed disease 
   Existing disease 
          ≤12 months 
          >12 to ≤24 months 
          >24 months 
          Unknown 
 
114 (34.1) 
220 (65.9) 
4 (1.2) 
14 (4.2) 
202 (60.5) 
0 
 
113 (33.8) 
221 (66.2) 
10 (3.0) 
15 (4.5) 
195 (58.4) 
1 (0.3) 
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Title: Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer 
Study identifier NCT01958021, EudraCT 2013-003084-61, MONALEESA-2 
Analysis population  
(continuation) 
Previous treatment,  
n (%) 
     Neoadjuvant or  
     adjuvant chemotherapy 
     Neoadjuvant or  
     adjuvant ET 
          Anastrozole 
          Exemestane 
          Goserelin 
          Letrozole 
          Tamoxifen 
          Other 
 
 
 
146 (43.7) 
 
175 (52.4) 
47 (14.1) 
19 (5.7) 
6 (1.8) 
34 (10.2) 
140 (41.9) 
2 (0.6) 
 
 
 
145 (43.4) 
 
171 (51.2) 
42 (12.6) 
25 (7.5) 
3 (0.9) 
25 (7.5) 
145 (43.4) 
4 (1.2) 
Metastatic sites, n (%) 
     0 
     1 
     2 
     ≥3 
 
2 (0.6) 
100 (29.9) 
118 (35.3) 
114 (34.1) 
 
1 (0.3) 
117 (35.0) 
103 (30.8) 
113 (33.8) 
Site of metastases, n (%) 
     Breast 
     Bone 
          Any 
          Only 
     Visceral 
     Lymph nodes 
     Other 
 
8 (2.4) 
 
246 (73.7) 
69 (20.7) 
197 (59.0) 
133 (39.8) 
35 (10.5) 
 
11 (3.3) 
 
244 (73.1) 
78 (23.4) 
196 (58.7) 
123 (36.8) 
22 (6.6) 
Abbreviations: MBC = metastatic breast cancer, CR = complete response, PR = partial response, QoL = quality of life, ET = endocrine therapy, AI 
= aromatase inhibitor, CNS = central nervous system, ER = oestrogen receptor, PR = progesterone receptor, ECOG = Eastern Cooperative 
Oncology Group, NA = not available 
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Table 4: Risk of bias assessment on study level is based on EUnetHTA (Internal validity of randomised controlled tri-
als) [37] 
Criteria for judging risk of bias  Risk of bias 
Adequate generation of randomisation sequence: Randomisation was stratified according 
to the presence or absence of liver or lung metastases. Patients were not stratified accord-
ing to their molecular subtype. 
unclear 
Adequate allocation concealment: No information is given about the allocation conceal-
ment of the randomisation system. 
unclear 
Blinding:  
Patient double-blind study  yes 
Treating physician: double-blind study yes 
Outcome assessment: blinded central analysis of PFS by an independent 
review committee 
yes 
Selective outcome reporting unlikely: outcomes reported as pre-specified yes 
No other aspects which increase the risk of bias:  
consistency in reporting  
pre-planned interim analyses led to premature study termination, described in detail 
study funded by the manufacturer 
 
 
yes (low) 
yes (low) 
no (high) 
 
Risk of bias – study level low 
 
 
 
